116 related articles for article (PubMed ID: 32064638)
1. Increased collection efficiency of CD34+ cells after mobilization with preemptive use of plerixafor followed by leukocytapheresis on the same day.
Cid J; Castillo C; Marín P; Carbassé G; Herrera D; Monfort N; Fernández-Avilés F; Gutiérrez-García G; Martínez C; Rosiñol L; Suárez-Lledó M; Rovira M; Urbano-Ispizua Á; Lozano M
Transfusion; 2020 Apr; 60(4):779-785. PubMed ID: 32064638
[TBL] [Abstract][Full Text] [Related]
2. Impact of good and poor mobilizers on hematopoietic progenitor cell collection efficiency and product quality.
Azzouqa AM; Jouni K; Roy V; Zubair AC
J Clin Apher; 2019 Feb; 34(1):39-43. PubMed ID: 30426567
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation.
Stover JT; Shaw JR; Kuchibhatla M; Horwitz ME; Engemann AM
Biol Blood Marrow Transplant; 2017 Aug; 23(8):1290-1294. PubMed ID: 28411174
[TBL] [Abstract][Full Text] [Related]
4. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure.
Lefrère F; Mauge L; Réa D; Ribeil JA; Dal Cortivo L; Brignier AC; Aoun C; Larghéro J; Cavazzana-Calvo M; Micléa JM
Transfusion; 2013 Mar; 53(3):564-9. PubMed ID: 22725259
[TBL] [Abstract][Full Text] [Related]
5. Pegfilgrastim- versus filgrastim-based autologous hematopoietic stem cell mobilization in the setting of preemptive use of plerixafor: efficacy and cost analysis.
Costa LJ; Kramer C; Hogan KR; Butcher CD; Littleton AL; Shoptaw KB; Kang Y; Stuart RK
Transfusion; 2012 Nov; 52(11):2375-81. PubMed ID: 22404694
[TBL] [Abstract][Full Text] [Related]
6. Results of a Prospective Randomized, Open-Label, Noninferiority Study of Tbo-Filgrastim (Granix) versus Filgrastim (Neupogen) in Combination with Plerixafor for Autologous Stem Cell Mobilization in Patients with Multiple Myeloma and Non-Hodgkin Lymphoma.
Bhamidipati PK; Fiala MA; Grossman BJ; DiPersio JF; Stockerl-Goldstein K; Gao F; Uy GL; Westervelt P; Schroeder MA; Cashen AF; Abboud CN; Vij R
Biol Blood Marrow Transplant; 2017 Dec; 23(12):2065-2069. PubMed ID: 28797783
[TBL] [Abstract][Full Text] [Related]
7. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor and granulocyte-colony-stimulating factor (G-CSF) in patients with lymphoma and multiple myeloma previously failing mobilization with G-CSF with or without chemotherapy for autologous hematopoietic stem cell mobilization: the Austrian experience on a named patient program.
Worel N; Rosskopf K; Neumeister P; Kasparu H; Nachbaur D; Russ G; Namberger K; Witt V; Schloegl E; Zojer N; Linkesch W; Kalhs P; Greinix HT
Transfusion; 2011 May; 51(5):968-75. PubMed ID: 20880037
[TBL] [Abstract][Full Text] [Related]
9. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
10. Hematopoietic Progenitor Cell Mobilization with Ifosfamide, Carboplatin, and Etoposide Chemotherapy versus Plerixafor-Based Strategies in Patients with Hodgkin and Non-Hodgkin Lymphoma.
Dhakal B; Veltri LW; Fenske TS; Eastwood D; Craig MD; Cumpston A; Shillingburg A; Esselman J; Watkins K; Pasquini MC; D'Souza A; Hari P; Kanate AS; Hamadani M
Biol Blood Marrow Transplant; 2016 Oct; 22(10):1773-1780. PubMed ID: 27345140
[TBL] [Abstract][Full Text] [Related]
11. Plerixafor is safe and efficacious for mobilization of peripheral blood stem cells in pediatric patients.
Teusink A; Pinkard S; Davies S; Mueller M; Jodele S
Transfusion; 2016 Jun; 56(6):1402-5. PubMed ID: 27079854
[TBL] [Abstract][Full Text] [Related]
12. Differences in Cellular Composition of Peripheral Blood Stem Cell Grafts from Healthy Stem Cell Donors Mobilized with Either Granulocyte Colony-Stimulating Factor (G-CSF) Alone or G-CSF and Plerixafor.
Teipel R; Oelschlägel U; Wetzko K; Schmiedgen M; Kramer M; Rücker-Braun E; Hölig K; von Bonin M; Heidrich K; Fuchs A; Ordemann R; Kroschinsky F; Bornhäuser M; Hütter G; Schmidt H; Ehninger G; Schetelig J; Heidenreich F
Biol Blood Marrow Transplant; 2018 Nov; 24(11):2171-2177. PubMed ID: 29935214
[TBL] [Abstract][Full Text] [Related]
13. Rescue stem cell mobilization with plerixafor economizes leukapheresis in patients with multiple myeloma.
Hundemer M; Engelhardt M; Bruckner T; Kraeker S; Schmitt A; Sauer S; Neben K; Witzens-Harig M; Goldschmidt H; Ho AD; Wuchter P
J Clin Apher; 2014 Dec; 29(6):299-304. PubMed ID: 24771277
[TBL] [Abstract][Full Text] [Related]
14. Addition of plerixafor for CD34+ cell mobilization in six healthy stem cell donors ensured satisfactory grafts for transplantation.
Hauge AW; Haastrup EK; Sengeløv H; Minulescu L; Dickmeiss E; Fischer-Nielsen A
Transfusion; 2014 Apr; 54(4):1055-8. PubMed ID: 23944772
[TBL] [Abstract][Full Text] [Related]
15. Factors affecting successful mobilization with plerixafor: an Italian prospective survey in 215 patients with multiple myeloma and lymphoma.
Lanza F; Lemoli RM; Olivieri A; Laszlo D; Martino M; Specchia G; Pavone V; Imola M; Pasini A; Milone G; Scortechini I; Todisco E; Guggiari E; Cascavilla N; Martinelli G; Rambaldi A; Bosi A
Transfusion; 2014 Feb; 54(2):331-9. PubMed ID: 23781769
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics.
Li J; Hamilton E; Vaughn L; Graiser M; Renfroe H; Lechowicz MJ; Langston A; Prichard JM; Anderson D; Gleason C; Lonial S; Flowers CR; Kaufman JL; Waller EK
Transfusion; 2011 Oct; 51(10):2175-82. PubMed ID: 21492180
[TBL] [Abstract][Full Text] [Related]
17. Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma.
Cheng J; Schmitt M; Wuchter P; Buss EC; Witzens-Harig M; Neben K; Hundemer M; Hillengass J; Alexi R; Goldschmidt H; Chen BA; Ho AD; Schmitt A
Transfusion; 2015 Feb; 55(2):275-83. PubMed ID: 25117969
[TBL] [Abstract][Full Text] [Related]
18. Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
Chen YB; Le-Rademacher J; Brazauskas R; Kiefer DM; Hamadani M; DiPersio JF; Litzow MR; Craig M; Horwitz ME; Artz AS; McClune BL; Fernandez HF; Duong HK; Kobusingye H; Proue M; Drexler RJ; Horowitz MM; Shaw BE; Miller JP; Hosoba S; Waller EK; Devine SM
Blood Adv; 2019 Mar; 3(6):875-883. PubMed ID: 30890544
[TBL] [Abstract][Full Text] [Related]
19. Peripheral blood stem cell mobilization in multiple myeloma patients treat in the novel therapy-era with plerixafor and G-CSF has superior efficacy but significantly higher costs compared to mobilization with low-dose cyclophosphamide and G-CSF.
Chaudhary L; Awan F; Cumpston A; Leadmon S; Watkins K; Tse W; Craig M; Hamadani M
J Clin Apher; 2013 Oct; 28(5):359-67. PubMed ID: 23765597
[TBL] [Abstract][Full Text] [Related]
20. Comparison and cost analysis of three protocols for mobilization and apheresis of haematopoietic progenitor cells.
López-Castaño F; Manresa P; Díaz V; Arranz E; López J; Pérez M; Alda O; Hernández L
J Clin Apher; 2019 Aug; 34(4):461-467. PubMed ID: 30817045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
